Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists

被引：30
|
作者：
Curtis, NR
Diggle, HJ
Kulagowski, JJ
London, C
Grimwood, S
Hutson, PH
Murray, F
Richards, P
Macaulay, A
Wafford, KA
机构：
[1] Merck Sharp & Dohme Res Labs, Dept Med Chem, Ctr Res Neurosci, Harlow CM20 2QR, Essex, England
[2] Merck Sharp & Dohme Res Labs, Dept Behav Neurosci, Ctr Res Neurosci, Harlow CM20 2QR, Essex, England
[3] Merck Sharp & Dohme Res Labs, Dept Pharmacol, Ctr Res Neurosci, Harlow CM20 2QR, Essex, England
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 04期
关键词：
D O I：
10.1016/S0960-894X(02)01060-0
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Novel (E)-N-1-(benzyl)cinnamamidines were prepared and evaluated as NR2B subtype NMDA receptor ligands. Excellent affinity was achieved by appropriate substitution of either phenyl ring. The 2-methoxybenzyl compound 1h had similar to1000-fold lower IC50 in NR2B than NR2A-containing cells. Replacement of the styryl unit by 2-naphthl was well tolerated. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：693 / 696
页数：4
相关论文
共 50 条
  • [1] NR2B subtype-selective NMDA receptor antagonists: 2001-2004
    McCauley, JA
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (04) : 389 - 407
  • [2] Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists
    Layton, ME
    Kelly, MJ
    Rodzinak, KJ
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (07) : 697 - 709
  • [3] NR2B subtype selective NMDA receptor antagonists.
    McCauley, JA
    Claiborne, CF
    Theberge, CR
    Romano, JJ
    Billings, SB
    Libby, BE
    McIntyre, CJ
    Anderson, KD
    Michelson, SR
    Claremon, DA
    Freidinger, RM
    Bednar, RA
    Mosser, SD
    Gaul, SL
    Connolly, TM
    Condra, CL
    Xia, M
    Cunningham, ME
    Kiss, L
    Bednar, B
    Stump, GL
    Lynch, JJ
    Curtis, NR
    Diggle, HJ
    Kulagowski, JJ
    Macaulay, A
    Wafford, KA
    Koblan, KS
    Liverton, NJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U37 - U37
  • [4] Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists
    Tamiz, AP
    Cai, SX
    Zhou, ZL
    Yuen, PW
    Schelkun, RM
    Whittemore, ER
    Weber, E
    Woodward, RM
    Keana, JFW
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (17) : 3412 - 3420
  • [5] NR2B selective NMDA receptor antagonists
    Nikam, SS
    Meltzer, LT
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (10) : 845 - 855
  • [6] Oxamides as novel NR2B selective NMDA receptor antagonists
    Barta-Szalai, G
    Borza, I
    Bozó, É
    Kiss, C
    Agai, B
    Proszenyák, A
    Keserü, GM
    Gere, A
    Kolok, S
    Galgóczy, K
    Horváth, C
    Farkas, S
    Domány, G
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (15) : 3953 - 3956
  • [7] In vitro characterization of novel NR2B selective NMDA receptor antagonists
    Kiss, L
    Cheng, G
    Bednar, B
    Bednar, RA
    Bennett, PB
    Kane, SA
    McIntyre, CJ
    McCauley, JA
    Koblan, KS
    NEUROCHEMISTRY INTERNATIONAL, 2005, 46 (06) : 453 - 464
  • [8] NMDA receptor antagonists as analgesics: focus on the NR2B subtype
    Chizh, BA
    Headley, PM
    Tzschentke, TM
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (12) : 636 - 642
  • [9] NMDA NR2B subtype-selective receptor antagonists fail to antagonize electrically-precipitated seizures and elicit popping in mice
    Burket, Jessica A.
    Mastropaolo, John
    Rosse, Richard B.
    Katz, Elionora U.
    Deutsch, Stephen I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 (03) : 207 - 210
  • [10] Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists
    Borza, Istvan
    Kolok, Sandor
    Galgoczy, Kornel
    Gere, Aniko
    Horvath, Csilla
    Farkas, Sandor
    Greiner, Istvan
    Domany, Gyorgy
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (02) : 406 - 409
12345